
|Articles|July 8, 2008
New therapy enters trials
INO-8875, an Adenosine 1 agonist in Phase I testing for the treatment of glaucoma, has begun patient enrolment.
Advertisement
Newsletter
Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.
Advertisement
Latest CME
Advertisement
Advertisement















































